Zacks: Analysts Anticipate LeMaitre Vascular Inc (LMAT) Will Post Earnings of $0.19 Per Share

Wall Street brokerages expect LeMaitre Vascular Inc (NASDAQ:LMAT) to post $0.19 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for LeMaitre Vascular’s earnings. LeMaitre Vascular also posted earnings per share of $0.19 in the same quarter last year. The company is scheduled to announce its next earnings results on Wednesday, April 24th.

On average, analysts expect that LeMaitre Vascular will report full-year earnings of $0.84 per share for the current financial year, with EPS estimates ranging from $0.82 to $0.85. For the next fiscal year, analysts anticipate that the company will post earnings of $0.94 per share, with EPS estimates ranging from $0.90 to $1.00. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover LeMaitre Vascular.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Tuesday, February 19th. The medical instruments supplier reported $0.24 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.24. The company had revenue of $28.39 million for the quarter, compared to analyst estimates of $26.06 million. LeMaitre Vascular had a return on equity of 17.71% and a net margin of 21.73%.

LMAT has been the topic of a number of research analyst reports. BidaskClub raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Thursday, December 13th. Lake Street Capital reaffirmed a “hold” rating and set a $24.00 price target on shares of LeMaitre Vascular in a research report on Wednesday, January 23rd. ValuEngine lowered LeMaitre Vascular from a “hold” rating to a “sell” rating in a research report on Monday, January 7th. Roth Capital reaffirmed a “neutral” rating on shares of LeMaitre Vascular in a research report on Thursday, February 21st. Finally, Zacks Investment Research lowered LeMaitre Vascular from a “hold” rating to a “sell” rating in a research report on Thursday, February 7th. One analyst has rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company. LeMaitre Vascular currently has a consensus rating of “Hold” and an average price target of $33.29.

Shares of NASDAQ LMAT traded down $0.26 during mid-day trading on Friday, reaching $29.82. 74,000 shares of the company’s stock were exchanged, compared to its average volume of 155,952. The firm has a market cap of $581.00 million, a P/E ratio of 27.73, a P/E/G ratio of 2.94 and a beta of 1.05. LeMaitre Vascular has a twelve month low of $21.79 and a twelve month high of $41.28.

In related news, insider Trent G. Kamke sold 16,604 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, February 22nd. The stock was sold at an average price of $29.63, for a total value of $491,976.52. Following the sale, the insider now owns 19,857 shares of the company’s stock, valued at approximately $588,362.91. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 20.30% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of LMAT. BlackRock Inc. boosted its stake in LeMaitre Vascular by 4.9% in the 3rd quarter. BlackRock Inc. now owns 2,545,148 shares of the medical instruments supplier’s stock valued at $98,599,000 after purchasing an additional 119,694 shares during the period. JPMorgan Chase & Co. lifted its position in shares of LeMaitre Vascular by 35.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 15,376 shares of the medical instruments supplier’s stock valued at $595,000 after acquiring an additional 4,020 shares during the period. MetLife Investment Advisors LLC lifted its position in shares of LeMaitre Vascular by 58.0% during the 3rd quarter. MetLife Investment Advisors LLC now owns 12,092 shares of the medical instruments supplier’s stock valued at $468,000 after acquiring an additional 4,441 shares during the period. Wells Fargo & Company MN lifted its position in shares of LeMaitre Vascular by 51.8% during the 3rd quarter. Wells Fargo & Company MN now owns 220,289 shares of the medical instruments supplier’s stock valued at $8,533,000 after acquiring an additional 75,165 shares during the period. Finally, Cadence Capital Management LLC lifted its position in shares of LeMaitre Vascular by 20.1% during the 3rd quarter. Cadence Capital Management LLC now owns 83,497 shares of the medical instruments supplier’s stock valued at $3,235,000 after acquiring an additional 13,984 shares during the period. 81.78% of the stock is currently owned by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Featured Story: How to Invest in an Index Fund

Get a free copy of the Zacks research report on LeMaitre Vascular (LMAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit